Skip to main content
OpenTrials
Completed

NCT Number: NCT05829382

A Study of Biological Effects of a Polyphenol Supplement

A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product "DailyColors™" (DC) on age-related pathways in adults.

The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers.

Based on power calculations a sample size of 20, is sufficient to detect an effect size of 0.46 at a power > 90%. To account for dropout the investigators will include 26 subjects in total.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

55 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stavanger Universitetssjukehus

Stavanger, Norway

About this study

Aims:

The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers.

Hypotheses:

There will be preliminary evidence that the IP has positive clinical effects on biologically relevant pathways related to healthy aging of brain and muscle including blood markers of inflammation, oxidative stress markers, and trophic factors.

Design:

A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product (DailyColors™) on age-related pathways in adults. Participants will receive DailyColors™ or placebo for a week, then one week wash-out, and then placebo/Dailycolors™ for a week, in random order. In addition, participants will be invited to participate in an open-label extension study for 3 months.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, (NB Equal number of male and female participants)
  • Age between 55 and 80
  • Body Mass Index (BMI) over 25 (since this group is expected to have a some degree of inflammation and other metabolic changes and more likely to respond to the supplement)
  • Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits
  • Provided voluntary, written, informed consent to participate in the study.

Exclusion criteria

  • Alcohol or drug abuse in past year
  • Subject has a known allergy to the test material's active or inactive ingredients
  • Subjects with unstable, life-threatening medical conditions
  • Use of polyphenol or phytochemical supplements
  • Use of dietary supplements last month, except from cod liver oil or other vitamin D supplements
  • Vegetarians and Vegans
  • Clinically significant abnormal laboratory results at screening
  • Participation in a clinical research trial within 30 days prior to randomization
  • Individuals with dementia and/or who are unable to give informed consent
  • Individuals with unusual high intake of fruit, berries, vegetable and/ or coffee intake, > 5 portions of fruit, berries and/or vegetables per day or > 5 cups of coffee per day
  • Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.

Treatment and study plan

DailyColors™

Dietary Supplement

Capsule containing active ingredient administred daily by the participant during the trial period

Placebo

Dietary Supplement

Capsule containing placebo administered daily by the participant during the trial period

Primary outcomes

  1. Blood levels of CD38

    Time frame: 3 weeks

    Change from baseline in the blood levels of CD38 at 1hour, 2 hours, 24 hours and week 1 and week 3. Blood CD38 is measured using commercially available immunoassays.

  2. Blood levels of NAD+

    Time frame: 3 weeks

    Change from baseline in the blood levels of NAD+ at 1hour, 2 hours, 24 hours and week 1 and 3. Blood NAD+ is measured using commercially available assay kits.

Secondary outcomes

  1. Blood levels of biomarkers for inflammation

    Time frame: 3 weeks

    Change from baseline in the blood levels of inflammatory biomarkers, such as IL-6, TNF-α and IL-10, and IL-8 at week 1 and 3. All blood biomarkers are measured using commercially available immunoassays. All biomarkers have the same unit of measure, namely pg/mL.

  2. Blood-based measurement of total antioxidant capacity

    Time frame: 3 weeks

    Change from baseline in the blood-based total antioxidant capacity at week 1 and 3, which are measured using commercially available assays.

  3. Blood levels of 4-HNE

    Time frame: 3 weeks

    Change from baseline in the blood levels of 4-HNE at week 1 and week 3, which are measured using commercially available assays.

  4. Blood levels of protein carbonyl

    Time frame: 3 weeks

    Change from baseline in the blood levels of protein carbonyl at week 1 and week 3, which are measured using commercially available assays.

Sponsors and collaborators

Lead sponsor

Helse Stavanger HF

Other Gov

Registry information

Official study title

A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement

Acronym: MIDI

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Apr 25, 2023
Registry last updated
May 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.